不同尖端与长度导管用于重症监护室连续肾脏替代治疗患者的随机对照试验
该开放标签三臂随机对照试验纳入351例接受CRRT的危重患者,随机分为20cm侧孔导管组(A组)、20cm阶梯尖端导管组(B组)和25cm阶梯尖端导管组(C组)。主要结局为导管功能障碍发生率和导管生存时间。A组导管功能障碍发生率35.7%(51/143)显著高于B组17.7%(22/124)(P=0.001),B组与C组无差异(15.6%,23/147,P=0.744)。A组与B组导管生存时间相当(5.5天 vs 5.0天,P=0.626),C组较B组显著延长(6.4天 vs 5.0天,P=0.019)。BMI为导管功能障碍独立危险因素(HR 1.052,95%CI 1.003-1.103,P=0.036),结果在不同BMI三分位间不一致,仅在BMI<24.2患者中观察到类似结果(卡方13.65,P=0.001)。C组有滤器寿命延长(36.5h,IQR 16.9-68.1,P=0.001)和导管相关血栓发生率降低(10.40/1000导管日,95%CI 5.93-17.83,P=0.019)的趋势。
要点
- 在ICU接受CRRT的危重患者中,20cm阶梯尖端导管组导管功能障碍发生率17.7%(22/124)显著低于20cm侧孔导管组35.7%(51/143)(P=0.001)。
- 25cm阶梯尖端导管组与20cm阶梯尖端导管组导管功能障碍发生率无差异(15.6%,23/147 vs 17.7%,22/124,P=0.744)。
- 25cm阶梯尖端导管组导管生存时间6.4天(IQR 3.9-12.0)较20cm阶梯尖端导管组5.0天(IQR 3.0-10.0)显著延长(P=0.019);20cm侧孔导管组与20cm阶梯尖端导管组无差异(5.5天 vs 5.0天,P=0.626)。
- BMI是导管功能障碍的独立危险因素(HR 1.052,95%CI 1.003-1.103,P=0.036),但结果在不同BMI三分位间不一致,仅在BMI<24.2患者中观察到类似结果(卡方13.65,P=0.001)。
- 25cm阶梯尖端导管组有滤器寿命延长(36.5h,IQR 16.9-68.1,P=0.001)和导管相关血栓发生率降低(10.40/1000导管日,95%CI 5.93-17.83,P=0.019)的趋势。
适用人群与场景
- 在重症监护室接受连续肾脏替代治疗的危重患者。
处置流程与药物剂量
- A组使用20cm侧孔导管(GDHK-1120),B组使用20cm阶梯尖端导管(GDHK-1320),C组使用25cm阶梯尖端导管(GDHK-1325)。
研究设计与关键结果
- 开放标签三臂随机对照试验,纳入351例接受CRRT的危重患者,A组116例、B组117例、C组118例。
- 主要结局导管功能障碍发生率:A组35.7%(51/143)显著高于B组17.7%(22/124)(P=0.001);B组与C组(15.6%,23/147)无差异(P=0.744)。
- 导管生存时间:A组5.5天(IQR 2.5-9.3)与B组5.0天(IQR 3.0-10.0)相当(P=0.626);C组6.4天(IQR 3.9-12.0)较B组显著延长(P=0.019)。
- Cox回归分析显示BMI是导管功能障碍的独立危险因素(HR 1.052,95%CI 1.003-1.103,P=0.036);结果在不同BMI三分位间不一致,仅在BMI<24.2患者中观察到类似结果(卡方13.65,P=0.001)。
- C组有滤器寿命延长(36.5h,IQR 16.9-68.1,P=0.001)和导管相关血栓发生率降低(10.40/1000导管日,95%CI 5.93-17.83,P=0.019)的趋势;其他次要结局组间无显著差异。
证据类型、等级与局限
- 证据类型:开放标签三臂随机对照试验(RCT)。
- 局限:原文未报告局限性;作者在结论中提出需要进一步高质量、多中心RCT来加强CRRT导管选择的证据。
对床旁实践的改变
- 作者认为,阶梯尖端导管可能更适于CRRT,尤其是BMI较低三分位的患者。
- 作者认为,较长的股静脉导管置入在CRRT中显示出增强的获益,尤其是在肥胖患者中。
指南或共识出处
- 试验注册号:ChiCTR2300075107,注册日期2023年8月25日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The tip design and length of catheter impact catheter function. Two types of catheters with different tips, side-hole catheters and step-tip catheters, are commonly used during continuous renal replacement therapy (CRRT). However, there is insufficient evidence comparing their efficacy and safety in CRRT. In addition, whether the insertion of a longer catheter could enhance catheter function remains poorly studied and controversial.
METHODS: In this open-label, three-arm, randomized trial, critically ill patients receiving CRRT were randomized to three groups. Group A received 20 cm side-hole catheters (GDHK-1120), group B received 20 cm step-tip catheters (GDHK-1320) and group C received 25 cm step-tip catheters (GDHK-1325). The primary outcomes were the incidence of catheter dysfunction and catheter survival time.
RESULTS: A total of 351 patients were enrolled, with 116 in group A, 117 in group B, and 118 in group C. The incidence of catheter dysfunction in group A (35.7%, 51/143) was significantly higher than that in group B (17.7%, 22/124) (P = 0.001). However, there was no difference between group B and group C (15.6%, 23/147) (P = 0.744). The catheter survival time was comparable between group A (5.5 days, IQR 2.5-9.3) and group B (5.0 days, IQR 3.0-10.0) (P = 0.626). In contrast, group C (6.4 days, IQR 3.9-12.0) demonstrated a significantly longer catheter survival time compared to group B (P = 0.019). Cox regression analysis identified BMI (HR 1.052, 95% CI 1.003-1.103, P = 0.036) as an independent risk factor for catheter dysfunction. Results were not consistent across BMI tertiles, with similar results observed only in patients with a lower BMI (BMI < 24.2) (chi-square 13.65, P = 0.001). There was also a trend that patients in group C have a longer filter lifespan (36.5 h, IQR 16.9-68.1, P = 0.001) and a lower incidence of catheter-related thrombosis (10.40 per 1000 catheter-days, 95% CI 5.93, 17.83, P = 0.019). Other secondary outcomes were not significantly different among groups.
CONCLUSIONS: Step-tip catheters may be preferable for CRRT, particularly for patients in the lower BMI tercile. Longer femoral vein catheterization demonstrated enhanced benefits in CRRT, especially among obese patients. Further high-quality, multicenter RCTs are essential to strengthen the evidence guiding catheter selection during CRRT.
TRIAL REGISTRATION: ChiCTR2300075107. Registered 25 August 2023.
参考来源
- Zhou Z, Liu C, Li P, et al. A randomized controlled trial of catheters with different tips and lengths for patients requiring continuous renal replacement therapy in intensive care unit. Crit Care. 2025. PMID: 40217330. doi:10.1186/s13054-025-05389-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。